# Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

> **NCT00633594** · PHASE1,PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 39 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00633594
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2015-04
- **Final completion:** 2016-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2017-01-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633594, "Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00633594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*